ArticleBiophysical journal2026
Chlorpromazine inhibits EAG1 channels by altering the interdomain coupling.
Article in Biophysical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New insights into the physiological, pathological and pharmacological roles of voltage‑gated potassium channel Kv10.1 in cancer (Review).International journal of oncology · 2026Review
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
EAG1 depolarization-activated potassium selective channels are important targets for treatment of cancer and neurological disorders. EAG1 channels are formed by a tetrameric subunit assembly with each subunit containing an N-terminal Per-Arnt-Sim (PAS) domain and C-terminal cyclic nucleotide-binding homology (CNBH) domain. The PAS and CNBH domains from adjacent subunits interact and form an intracellular tetrameric ring that regulates the EAG1 channel gating, including the movement of the voltage sensor domain (VSD) from closed to open states. Small-molecule ligands can inhibit EAG1 channels by binding to their PAS domains. However, the allosteric pathways of this inhibition are not known. Here, we combined molecular dynamics (MD) simulations, network analysis, surface plasmon resonance (SPR), and mutagenesis-coupled electrophysiology to investigate the allosteric pathways of EAG1 channel regulation by a small-molecule ligand. MD simulations and network analysis revealed that chlorpromazine, a PAS domain small-molecule binder, alters interactions between the PAS and CNBH domains. Consistent with computational predictions, chlorpromazine affected interactions between the isolated PAS and CNBH domains probed with SPR. Our network analysis also indicated that binding chlorpromazine to the PAS domain alters coupling between all major regulatory domains of EAG1, including the intracellular PAS/CNBH domain ring, VSD and pore of the channel. Interestingly, chlorpromazine binding to the PAS domain did not substantially alter Cole-Moore shift characteristic of EAG1 channels, suggesting that chlorpromazine has little effect on the VSD movement from the deep closed to opened states. This further suggests that, if chlorpromazine binding alters coupling between the PAS/CNBH domain ring, VSD, and pore, as predicted by the network analysis, these alterations occur at potential more depolarized than the ones eliciting the Cole-Moore shift. Taken together, our study provides an insight into the allosteric pathways of EAG1 channel regulation by small-molecule PAS domain binders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.